ATE508126T1 - Als kinaseinhibitoren geeignete aminopyrimidine - Google Patents

Als kinaseinhibitoren geeignete aminopyrimidine

Info

Publication number
ATE508126T1
ATE508126T1 AT06837883T AT06837883T ATE508126T1 AT E508126 T1 ATE508126 T1 AT E508126T1 AT 06837883 T AT06837883 T AT 06837883T AT 06837883 T AT06837883 T AT 06837883T AT E508126 T1 ATE508126 T1 AT E508126T1
Authority
AT
Austria
Prior art keywords
aminopyrimidines
compounds
kinase inhibitors
compositions
inhibitors
Prior art date
Application number
AT06837883T
Other languages
English (en)
Inventor
Damien Fraysse
Andrew Miller
Daniel Robinson
Joanne Pinder
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE508126T1 publication Critical patent/ATE508126T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06837883T 2005-11-16 2006-11-16 Als kinaseinhibitoren geeignete aminopyrimidine ATE508126T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73706405P 2005-11-16 2005-11-16
PCT/US2006/044636 WO2007059299A1 (en) 2005-11-16 2006-11-16 Aminopyrimidines useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE508126T1 true ATE508126T1 (de) 2011-05-15

Family

ID=37806123

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06837883T ATE508126T1 (de) 2005-11-16 2006-11-16 Als kinaseinhibitoren geeignete aminopyrimidine

Country Status (9)

Country Link
US (1) US20070179125A1 (de)
EP (1) EP1951716B1 (de)
JP (1) JP2009515992A (de)
CN (1) CN101360740A (de)
AT (1) ATE508126T1 (de)
AU (1) AU2006315334B2 (de)
CA (1) CA2629781A1 (de)
DE (1) DE602006021776D1 (de)
WO (1) WO2007059299A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ATE346064T1 (de) 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
AU2006304897B2 (en) * 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
JP5249770B2 (ja) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン
EP2606890A1 (de) * 2006-04-05 2013-06-26 Novartis AG Kombinationen aus BCR-ABL/C-KIT/PDGF-R TK-Hemmern zu Krebsbehandlung
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
NZ572072A (en) 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
EP2086965B1 (de) 2006-11-02 2010-02-10 Vertex Pharmaceuticals, Inc. Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
DE602007007985D1 (de) * 2006-12-19 2010-09-02 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
MX2009009592A (es) 2007-03-09 2009-11-10 Vertex Pharma Aminopiridinas utiles como inhibidores de proteinas cinasas.
KR20090120510A (ko) * 2007-03-09 2009-11-24 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 아미노피리미딘
CA2679884A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AU2008247592A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
JP5389786B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
AU2008282156B2 (en) 2007-07-31 2014-07-17 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
JP2010538003A (ja) * 2007-08-29 2010-12-09 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
EP3078662A1 (de) * 2007-09-21 2016-10-12 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazol derivate als glucokinase aktivatoren zur behandlung von diabetes mellitus
WO2009073224A1 (en) * 2007-12-07 2009-06-11 Ambit Biosciences Corp. Methods of treating certain diseases using pyrimidine derivatives
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20110129467A1 (en) * 2008-07-24 2011-06-02 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135984A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137843A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
EP2408769A1 (de) 2009-03-17 2012-01-25 Glaxo Group Limited Als itk-inhibitoren verwendete pyrimidinderivate
EP2411011A4 (de) * 2009-03-24 2012-08-15 Msd Kk Neue aminopyridinderivate mit selektiver aurora-a-hemmung
JP2014524456A (ja) 2011-08-25 2014-09-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト セリン/スレオニンpak1阻害剤
WO2013092940A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag 2, 4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
MX2014011115A (es) 2012-03-16 2015-03-13 Axikin Pharmaceuticals Inc Inhibidores de 3,5-diaminopirazol cinasa.
RS61664B1 (sr) 2012-04-24 2021-04-29 Vertex Pharma Inhibitori dna-pk
CA2876539A1 (en) * 2012-06-15 2013-12-19 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
SI3424920T1 (sl) 2013-10-17 2020-08-31 Vertex Pharmaceuticals Incorporated Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
WO2016197009A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
KR101726648B1 (ko) * 2016-02-29 2017-04-14 한국화학연구원 신규한 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 drak 관련 질환의 예방 또는 치료용 약학적 조성물
AU2017258186B2 (en) 2016-04-28 2020-09-17 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as JAK kinase inhibitors
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
US11440898B2 (en) 2016-12-28 2022-09-13 Minoryx Therapeutics S.L. Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
CN106841420A (zh) * 2016-12-30 2017-06-13 广州中大南沙科技创新产业园有限公司 一种LC‑MS/MS测定大鼠血浆中Ly‑7u浓度的方法
AU2018354370B2 (en) 2017-10-27 2023-04-27 Theravance Biopharma R&D Ip, Llc Pyrimidine compound as JAK kinase inhibitor
EP3856349A1 (de) * 2018-09-25 2021-08-04 Black Diamond Therapeutics, Inc. Tyrosinkinase-inhibitorzusammensetzungen, verfahren zu ihrer herstellung und ihre verwendung
HRP20241053T1 (hr) 2019-04-24 2024-11-08 Theravance Biopharma R&D Ip, Llc Pirimidinski inhibitori jak, namijenjeni liječenju kožnih bolesti
AR118768A1 (es) 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Derivados de pirimidina como inhibidores de las cinasas jak
BR112023003517A2 (pt) * 2020-08-26 2023-05-09 Nalo Therapeutics Moduladores da proteína proto-oncogênica da família myc
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US20250177393A1 (en) * 2022-02-25 2025-06-05 Nalo Therapeutics Modulators of myc family proto-oncogene protein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4794793B2 (ja) * 1999-12-28 2011-10-19 ファーマコペイア, インコーポレイテッド N−ヘテロ環TNF−α発現阻害剤
ATE354573T1 (de) * 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
HUP0402352A2 (hu) * 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
KR20060123164A (ko) * 2003-10-17 2006-12-01 아스트라제네카 아베 암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
JP5249770B2 (ja) * 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン

Also Published As

Publication number Publication date
WO2007059299A1 (en) 2007-05-24
EP1951716A1 (de) 2008-08-06
US20070179125A1 (en) 2007-08-02
AU2006315334B2 (en) 2011-05-19
CN101360740A (zh) 2009-02-04
AU2006315334A1 (en) 2007-05-24
JP2009515992A (ja) 2009-04-16
CA2629781A1 (en) 2007-05-24
DE602006021776D1 (de) 2011-06-16
EP1951716B1 (de) 2011-05-04

Similar Documents

Publication Publication Date Title
ATE508126T1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
TW200736249A (en) Aminopyrimidines useful as kinase inhibitors
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE493401T1 (de) Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen
MX2009004771A (es) Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
ATE542814T1 (de) Pyrazinkinaseinhibitoren
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
TW200745088A (en) Benzimidazoles useful as inhibitors of protein kinases
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties